Categories AlphaGraphs, Analysis, Health Care

Amarin earnings preview: Expect higher revenues, but wider losses in Q1

Amarin Corporation (NASDAQ: AMRN) is scheduled to report first-quarter 2019 earnings results on Wednesday, May 1, before the opening bell. Analysts expect the biopharmaceutical firm to report a loss of $0.11 per share during the quarter, four cents wider than the loss it posted last year.

The bottom line will likely feel the pressure as the Dublin-based firm shells out more money on the promotion and marketing of its Vascepa capsules. The company will also incur charges related to its label expansion applications.

Vascepa lowers fat level in blood by reducing triglycerides in the body when taken along with a proper diet.

Amarin's Q4 2018 prescription growth trend for Vascepa

Revenue is expected to jump about 64% to $72.2 million, riding on the strong demand for its Vascepa capsules. Separately, as Amarin expands the sale of Vascepa across international markets, it is set to receive higher commercialization fees from its licensed partners.

Earlier today, the company announced that it has filed a New Drug Submission with Health Canada for Vascepa.

Amarin shares have gained 46% since the beginning of this year, outperforming the industry which has grown just over 2%. Three events had set the stage for the stock rally this year: Rumors that Novartis (NYSE: NVS) was interested in acquiring it; a better-than-expected revenue growth in Q4; and reports that the American Diabetes Association had given a positive note on its Vascepa capsule.

In Q4

In the last reported quarter, Amarin surpassed analysts’ expectations on revenues, while net loss came in higher-than-expected. Shares rose 3.9% in premarket hours on Wednesday.

READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS

Total revenues of $77.3 million were up 44% year-over-year, primarily reflecting Vascepa prescription growth. Net product revenue totaled $77.1 million, mainly due to increased Vascepa prescriptions in the US.

The stock has a 12-month price target of $38.67, suggesting a 100% upside from the last close.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Tyson Foods (TSN) Q1 2023 Earnings: Key financials and quarterly highlights

Tyson Foods Inc. (NYSE: TSN) reported first quarter 2023 earnings results today. Sales rose 2.5% year-over-year to $13.2 billion. Net income attributable to Tyson was $316 million, or $0.88 per

After weak start to 2023, Apple (AAPL) sees some bright spots

Apple Inc. (NASDAQ: AAPL) this week reported its first revenue decline in more than three years, even as the high inflation continues to squeeze customers’ spending power. Sales of the

Earnings: Qualcomm (QCOM) Q1 profit falls on lower revenues

Chipmaker Qualcomm, Inc. (NASDAQ: QCOM) has reported lower earnings and revenues for the first quarter of 2023. The company also provided guidance for the second quarter of 2023. At $9.5

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top